Rapid-acting insulins

Switching 1% of standard bolus insulin lispro to a liver-targeted formulation decreases hypoglycemic events without affecting glucose control, OPTI-1 study findings indicate.

Ultra-rapid lispro gives equivalent overall glycemic control to standard lispro, and is significantly better for some postprandial measurements in children with type 1 diabetes, shows the PRONTO-Peds trial.

Results of a phase 1 study show that a concentrated version of insulin aspart not only provides a smaller injection volume but also has a more rapid onset of action than the standard version.

Switching to fast-acting insulin aspart is associated with an increased time in range and reduced glycemic variability, show data from a real-world observational study.

Click through to read more on this announcement

A co-formulation of pramlintide and a prandial insulin offers improved postprandial glucose control and weight loss, without an increased number of injections, show the results of a small crossover trial.

Switching to fast-acting insulin aspart significantly improves glycemic control and time in glucose target range in people with type 1 diabetes using continuous glucose monitoring, data from the real-world GoBolus study show.

A fully automated dual-hormone delivery system with pramlintide and faster-acting insulin aspart delivers overall glycemic control that is nearly as good as that achieved with a hybrid closed-loop system with the insulin only, report researchers at the virtual 56th EASD Annual Meeting.